InnoCare Pharma Future Growth
Future criteria checks 2/6
InnoCare Pharma is forecast to grow earnings and revenue by 18.7% and 26.7% per annum respectively. EPS is expected to grow by 23.6% per annum. Return on equity is forecast to be -8.6% in 3 years.
Key information
18.7%
Earnings growth rate
23.6%
EPS growth rate
| Biotechs earnings growth | 40.0% |
| Revenue growth rate | 26.7% |
| Future return on equity | -8.6% |
| Analyst coverage | Good |
| Last updated | 03 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,833 | -274 | 439 | -427 | 8 |
| 12/31/2025 | 1,325 | -525 | 340 | -543 | 8 |
| 12/31/2024 | 949 | -602 | N/A | -391 | 7 |
| 6/30/2024 | 781 | -471 | -835 | -638 | N/A |
| 3/31/2024 | 715 | -761 | -832 | -595 | N/A |
| 12/31/2023 | 739 | -631 | -920 | -665 | N/A |
| 9/30/2023 | 721 | -584 | -759 | -541 | N/A |
| 6/30/2023 | 757 | -867 | -817 | -607 | N/A |
| 3/31/2023 | 696 | -781 | -716 | -507 | N/A |
| 12/31/2022 | 625 | -887 | -861 | -491 | N/A |
| 9/30/2022 | 503 | -987 | -888 | -508 | N/A |
| 6/30/2022 | 1,187 | -296 | -229 | 150 | N/A |
| 3/31/2022 | 1,111 | -78 | -226 | 117 | N/A |
| 12/31/2021 | 1,043 | -65 | -4 | 167 | N/A |
| 9/30/2021 | 982 | 60 | 49 | 239 | N/A |
| 6/30/2021 | 102 | -266 | -464 | -258 | N/A |
| 3/31/2021 | 52 | -329 | -444 | -215 | N/A |
| 12/31/2020 | 1 | -391 | -424 | -173 | N/A |
| 9/30/2020 | 1 | -1,853 | -393 | -148 | N/A |
| 6/30/2020 | 1 | -2,155 | -320 | -137 | N/A |
| 3/31/2020 | 1 | -2,148 | -237 | -108 | N/A |
| 12/31/2019 | 1 | -2,141 | -155 | -80 | N/A |
| 9/30/2019 | 2 | -742 | -43 | -30 | N/A |
| 6/30/2019 | 2 | -592 | -22 | -17 | N/A |
| 3/31/2019 | 2 | -571 | -30 | -18 | N/A |
| 12/31/2018 | 2 | -550 | -38 | -18 | N/A |
| 12/31/2017 | 0 | -342 | N/A | -49 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9969 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9969 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9969 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9969's revenue (26.7% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
High Growth Revenue: 9969's revenue (26.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9969 is forecast to be unprofitable in 3 years.